Catalyst Pharmaceuticals Reaffirms 2024 Total Revenue Guidance Of $455M – $475M, Expecting Results In Upper Range Of Range; Est $462.433M
Portfolio Pulse from Benzinga Newsdesk
Catalyst Pharmaceuticals has reaffirmed its 2024 total revenue guidance of $455M to $475M, expecting results in the upper range of this range. The estimated revenue is $462.433M.
August 07, 2024 | 9:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Catalyst Pharmaceuticals has reaffirmed its 2024 total revenue guidance of $455M to $475M, expecting results in the upper range of this range. The estimated revenue is $462.433M.
Reaffirming revenue guidance and expecting results in the upper range is a positive signal for investors, indicating strong performance and potential for stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100